Ibuakut (Ibuprofen)

Ibuprofen works by blocking the cyclooxygenase enzymes COX‑1 and COX‑2, which are responsible for converting arachidonic acid into prostaglandins. Prostaglandins mediate pain, fever, and inflammation, so their reduction leads to analgesic, antipyretic, and anti‑inflammatory effects.

The appropriate dose of Ibuakut is set by the prescribing clinician based on the patient’s age, weight, medical condition, and response to therapy. Dosage recommendations follow local prescribing guidelines and should not be altered without medical advice.

Ibuprofen should be avoided in the third trimester of pregnancy because it may affect fetal cardiovascular function. Use during the first two trimesters or while breastfeeding should only be considered if the benefits outweigh potential risks and after consulting a healthcare provider.

To place an order, submit an enquiry on the Ibuakut product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ibuakut (ibuprofen) offers a balance of analgesic, antipyretic and anti‑inflammatory activity that is comparable to other non‑selective NSAIDs such as naproxen or diclofenac. Choice of agent often depends on individual patient tolerance, dosing frequency, and specific safety considerations like gastrointestinal or cardiovascular risk.

Ibuakut should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Ibuakut is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food may reduce gastrointestinal discomfort. The exact administration schedule is determined by the prescribing clinician.

Serious risks include gastrointestinal bleeding or ulcer perforation, severe allergic reactions such as anaphylaxis, acute kidney injury, and increased cardiovascular events in high‑risk patients. Patients should be monitored for signs of these events and seek immediate medical attention if they occur.

Ibuakut should be avoided in individuals with known hypersensitivity to ibuprofen or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, patients in the third trimester of pregnancy, and patients with severe renal or hepatic impairment unless specifically directed by a physician.